Document Detail

Treatment of intraventricular hemorrhage using urokinase.
MedLine Citation:
PMID:  1699149     Owner:  NLM     Status:  MEDLINE    
Four patients with severe intraventricular hemorrhage (IVH) were treated using urokinase administered into the lateral ventricles via a ventricular drainage catheter. All patients were female and of ages ranging from 24 to 53 years. The primary diseases were hemorrhagic infarction, moyamoya disease, sinus thrombosis, and thalamic bleeding. Urokinase administration was initiated at 1.3 days average after occurrence of IVH and continued for 3.3 days average in doses of 12,000-96,000 IU per day. Average clot lysis times from IVH, as assessed by computed tomography, were 5.0 +/- 0.8, 5.0 +/- 1.4, and 6.0 +/- 0.8 days for the fourth, the third, and the lateral ventricles, respectively. All patients suffered from meningitis which was probably caused by urokinase administration through a ventricular catheter. However, this was successfully treated by changing the antibiotics. There was no general bleeding tendency or intraventricular rebleeding due to urokinase administration, and none of the ventricular catheters were obstructed by clots throughout the course. The final outcome was good recovery in two patients, severe disability in one, and persistent vegetative state in one. These results correlated well with the consciousness level seen before ventricular drainage in each patient. Consequently, we are convinced that urokinase administration can prevent the harmful effects of IVH and that urokinase is useful not only for lysing ventricular clots but also for maintaining the patency of the ventricular catheter, which is important for control of intracranial pressure in the acute stage of severe IVH.
P H Shen; Y Matsuoka; K Kawajiri; M Kanai; K Hoda; S Yamamoto; S Nishimura
Related Documents :
10749299 - Factors influencing function of temporary dialysis catheters.
7827719 - Radiofrequency catheter ablation of sustained intraatrial reentrant tachycardia in a pa...
15919259 - Current status of cellular therapy for ischemic heart disease.
20025719 - Complete atrioventricular block during ablation of atrial flutter.
16105489 - Ablation of ventricular fibrillation and tachycardia.
20132399 - Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia.
22480839 - Recovery from decompensated heart failure is associated with a distinct, phase-dependen...
19356449 - Noninvasive imaging of angiotensin receptors after myocardial infarction.
22746169 - Ischemia-reperfusion increases transfection efficiency of intracoronary adenovirus type...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Neurologia medico-chirurgica     Volume:  30     ISSN:  0470-8105     ISO Abbreviation:  Neurol. Med. Chir. (Tokyo)     Publication Date:  1990 May 
Date Detail:
Created Date:  1990-11-02     Completed Date:  1990-11-02     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0400775     Medline TA:  Neurol Med Chir (Tokyo)     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  329-33     Citation Subset:  IM    
Department of Neurosurgery, Saiseikai Ibaraki Hospital, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cerebral Hemorrhage / therapy*
Cerebral Ventricles*
Cerebrospinal Fluid Shunts*
Combined Modality Therapy
Middle Aged
Urokinase-Type Plasminogen Activator / administration & dosage*
Reg. No./Substance:
EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is Chiari I malformation in the aged initiated by mechanical factors? Report of three cases.
Next Document:  Multicentric glioblastoma multiforme occurring in the supra- and the infratentorial regions--case re...